Shimadzu Corporation: Started contract analysis to estimate amyloid accumulation in the brain from blood
Contributing to basic research and development of therapeutic drugs and preventive methods for Alzheimer’s disease
On August 7, Shimadzu Techno-Research will commence contract analysis to estimate amyloid accumulation degree in the brain from plasma from the research and development field on Alzheimer’s dementia.
This technology is applied as a contract analysis service by applying the method published on Nature Online version on February 1, 2018 (Japan time).
Nature Article: A. Nakamura, N. Kaneko et. Al., “High performance plasma amyloid – β biomarkers for Alzheimer’s disease” doi: 10.1038 / nature 25456
2018 | News | Shimadzu Corporation